Back to search

Article

Complete Remission of a Patient With HER-2 amplification Gastric Cancer Treated With Sintilimab Combined With Trastuzumab

2023-04-17

Abstract excerpt

<h4>Background: </h4> Gastric cancer (GC) is one of the most common malignant tumors in China and is also a major cause of cancer deaths worldwide, for which treatment strategies are extremely limited. Patients Susually lose the opportunity of therapeutic surgery because the lesions cannot be completely removed, although it can greatly prolong their survival time. Human epidermal growth factor receptor-2（HER-2）is...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3680c87f-c47a-55ba-a8dd-c44625287898
DOI
10.21203/rs.3.rs-2797687/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Complete Remission of a Patient With HER-2 amplification Gastric Cancer Treated With Sintilimab Combined With TrastuzumabDOI 10.21203/rs.3.rs-2797687/v1
Sintilimab plus irinotecan, leucovorin and 5-fluorouracil (FOLFIRI) as salvage treatment for patients with advanced gastric cancer: real-world evidence from a single-centre cohortSemantic proximity
The Efficacy and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and Hormone Receptor-Positive/HER2-Negative Breast Cancer: A Multicenter Real-World Study from TurkeySemantic proximity
Genomic correlations for clinical outcomes in HER2-positive advanced gastric cancers treated using trastuzumab-based therapySemantic proximity
Trastuzumab in combination with capecitabine plus cisplatin for the treatment of advanced HER2-positive gastric cancer: A systematic review and meta-analysisSemantic proximity
The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyondSemantic proximity
Evaluation of ctDNA in Predicting Response to Neoadjuvant Therapy and Analysis of Residual Disease in Local Advanced Gastric Cancer: Protocol of A Single-Arm Multicenter Prospective Observational StudySemantic proximity
Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of Trastuzumab.Semantic proximity
Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.Semantic proximity
Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapySemantic proximity
Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancerSemantic proximity
Adebrelimab plus apatinib and SOX (AASOX) as conversion therapy for borderline resectable gastric cancer: a single-arm, single-centre, exploratory phase II studySemantic proximity
First-line pembrolizumab, trastuzumab, and chemotherapy in advanced HER2-positive gastric cancer with sequential genomic profilingSemantic proximity
Select a neighboring publication to make it the new centre.